Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

MICAL2 is expressed in cancer associated neo-angiogenic capillary endothelia and it is required for endothelial cell viability, motility and VEGF response.

Barravecchia I, Mariotti S, Pucci A, Scebba F, De Cesari C, Bicciato S, Tagliafico E, Tenedini E, Vindigni C, Cecchini M, Berti G, Vitiello M, Poliseno L, Mazzanti CM, Angeloni D.

Biochim Biophys Acta Mol Basis Dis. 2019 Sep 1;1865(9):2111-2124. doi: 10.1016/j.bbadis.2019.04.008. Epub 2019 Apr 18.

PMID:
31004710
2.

Systematic evaluation of the microRNAome through miR-CATCHv2.0 identifies positive and negative regulators of BRAF-X1 mRNA.

Marranci A, D'Aurizio R, Vencken S, Mero S, Guzzolino E, Rizzo M, Pitto L, Pellegrini M, Chiorino G, Greene CM, Poliseno L.

RNA Biol. 2019 Jul;16(7):865-878. doi: 10.1080/15476286.2019.1600934. Epub 2019 Apr 19.

PMID:
30929607
3.

Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib.

Schirripa M, Borelli B, D'Aurizio R, Lubrano S, Cremolini C, Zucchelli G, Antoniotti C, Marmorino F, Prete AA, Murgioni S, Bergamo F, Zagonel V, Tuccoli A, Marranci A, Rizzo M, Tedeschi L, Magnoni L, Falcone A, Loupakis F, Poliseno L.

Pharmacogenomics J. 2019 Oct;19(5):455-464. doi: 10.1038/s41397-019-0075-3. Epub 2019 Jan 28.

PMID:
30686821
4.

Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma.

Vitiello M, Evangelista M, Di Lascio N, Kusmic C, Massa A, Orso F, Sarti S, Marranci A, Rodzik K, Germelli L, Chandra D, Salvetti A, Pucci A, Taverna D, Faita F, Gravekamp C, Poliseno L.

Oncogene. 2019 May;38(19):3756-3762. doi: 10.1038/s41388-019-0681-1. Epub 2019 Jan 21.

5.

Development of a yeast-based system to identify new hBRAFV600E functional interactors.

Lubrano S, Comelli L, Piccirilli C, Marranci A, Dapporto F, Tantillo E, Gemignani F, Gutkind JS, Salvetti A, Chiorino G, Cozza G, Chiariello M, Galli A, Poliseno L, Cervelli T.

Oncogene. 2019 Feb;38(8):1355-1366. doi: 10.1038/s41388-018-0496-5. Epub 2018 Sep 20.

PMID:
30237439
6.

Biological role of miR-204 and miR-211 in melanoma.

Vitiello M, D'Aurizio R, Poliseno L.

Oncoscience. 2018 Aug 22;5(7-8):248-251. doi: 10.18632/oncoscience.443. eCollection 2018 Jul.

7.

Ensemble Modeling Approach Targeting Heterogeneous RNA-Seq data: Application to Melanoma Pseudogenes.

Capobianco E, Valdes C, Sarti S, Jiang Z, Poliseno L, Tsinoremas NF.

Sci Rep. 2017 Dec 11;7(1):17344. doi: 10.1038/s41598-017-17337-7.

8.

The landscape of BRAF transcript and protein variants in human cancer.

Marranci A, Jiang Z, Vitiello M, Guzzolino E, Comelli L, Sarti S, Lubrano S, Franchin C, Echevarría-Vargas I, Tuccoli A, Mercatanti A, Evangelista M, Sportoletti P, Cozza G, Luzi E, Capobianco E, Villanueva J, Arrigoni G, Signore G, Rocchiccioli S, Pitto L, Tsinoremas N, Poliseno L.

Mol Cancer. 2017 Apr 28;16(1):85. doi: 10.1186/s12943-017-0645-4.

9.

Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells.

Vitiello M, Tuccoli A, D'Aurizio R, Sarti S, Giannecchini L, Lubrano S, Marranci A, Evangelista M, Peppicelli S, Ippolito C, Barravecchia I, Guzzolino E, Montagnani V, Gowen M, Mercoledi E, Mercatanti A, Comelli L, Gurrieri S, Wu LW, Ope O, Flaherty K, Boland GM, Hammond MR, Kwong L, Chiariello M, Stecca B, Zhang G, Salvetti A, Angeloni D, Pitto L, Calorini L, Chiorino G, Pellegrini M, Herlyn M, Osman I, Poliseno L.

Oncotarget. 2017 Apr 11;8(15):25395-25417. doi: 10.18632/oncotarget.15915.

10.

Methods for the Identification of PTEN-Targeting MicroRNAs.

Tuccoli A, Vitiello M, Marranci A, Russo F, Poliseno L.

Methods Mol Biol. 2016;1388:111-38. doi: 10.1007/978-1-4939-3299-3_9.

PMID:
27033074
11.

Alkaline Phosphatase-Positive Immortal Mouse Embryo Fibroblasts Are Cells in a Transitional Reprogramming State Induced to Face Environmental Stresses.

Evangelista M, Baroudi ME, Rizzo M, Tuccoli A, Poliseno L, Pellegrini M, Rainaldi G.

Genet Epigenet. 2015 Dec 28;7:33-41. doi: 10.4137/GEG.S27696. eCollection 2015.

12.

Pseudogenes in Human Cancer.

Poliseno L, Marranci A, Pandolfi PP.

Front Med (Lausanne). 2015 Sep 25;2:68. doi: 10.3389/fmed.2015.00068. eCollection 2015. Review.

13.

Identification of BRAF 3'UTR Isoforms in Melanoma.

Marranci A, Tuccoli A, Vitiello M, Mercoledi E, Sarti S, Lubrano S, Evangelista M, Fogli A, Valdes C, Russo F, Monte MD, Caligo MA, Pellegrini M, Capobianco E, Tsinoremas N, Poliseno L.

J Invest Dermatol. 2015 Jun;135(6):1694-1697. doi: 10.1038/jid.2015.47. Epub 2015 Feb 16. No abstract available.

14.

Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.

Lunardi A, Varmeh S, Chen M, Taulli R, Guarnerio J, Ala U, Seitzer N, Ishikawa T, Carver BS, Hobbs RM, Quarantotti V, Ng C, Berger AH, Nardella C, Poliseno L, Montironi R, Castillo-Martin M, Cordon-Cardo C, Signoretti S, Pandolfi PP.

Cancer Discov. 2015 May;5(5):550-63. doi: 10.1158/2159-8290.CD-13-1050. Epub 2015 Feb 4.

15.

PTEN ceRNA networks in human cancer.

Poliseno L, Pandolfi PP.

Methods. 2015 May;77-78:41-50. doi: 10.1016/j.ymeth.2015.01.013. Epub 2015 Jan 30. Review.

PMID:
25644446
16.

Erratum to: Long non-coding RNAs in cancer: implications for personalized therapy.

Vitiello M, Tuccoli A, Poliseno L.

Cell Oncol (Dordr). 2015 Feb;38(1):91. doi: 10.1007/s13402-014-0202-8. No abstract available.

PMID:
25287373
17.

Long non-coding RNAs in cancer: implications for personalized therapy.

Vitiello M, Tuccoli A, Poliseno L.

Cell Oncol (Dordr). 2015 Feb;38(1):17-28. doi: 10.1007/s13402-014-0180-x. Epub 2014 Aug 12. Review. Erratum in: Cell Oncol (Dordr). 2015 Feb;38(1):91.

PMID:
25113790
18.

Preface. Pseudogenes.

Poliseno L.

Methods Mol Biol. 2014;1167:v. No abstract available.

PMID:
24940584
19.

Hedgehog pathway blockade inhibits melanoma cell growth in vitro and in vivo.

O'Reilly KE, de Miera EV, Segura MF, Friedman E, Poliseno L, Han SW, Zhong J, Zavadil J, Pavlick A, Hernando E, Osman I.

Pharmaceuticals (Basel). 2013 Nov 11;6(11):1429-50. doi: 10.3390/ph6111429.

20.

MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling.

Song SJ, Poliseno L, Song MS, Ala U, Webster K, Ng C, Beringer G, Brikbak NJ, Yuan X, Cantley LC, Richardson AL, Pandolfi PP.

Cell. 2013 Jul 18;154(2):311-324. doi: 10.1016/j.cell.2013.06.026. Epub 2013 Jul 3.

21.

Pseudogenes: newly discovered players in human cancer.

Poliseno L.

Sci Signal. 2012 Sep 18;5(242):re5. Review.

PMID:
22990117
22.

Histology-specific microRNA alterations in melanoma.

Poliseno L, Haimovic A, Segura MF, Hanniford D, Christos PJ, Darvishian F, Wang J, Shapiro RL, Pavlick AC, Berman RS, Hernando E, Zavadil J, Osman I.

J Invest Dermatol. 2012 Jul;132(7):1860-8. doi: 10.1038/jid.2011.451. Epub 2012 May 3.

23.

Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs.

Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, Karreth F, Poliseno L, Provero P, Di Cunto F, Lieberman J, Rigoutsos I, Pandolfi PP.

Cell. 2011 Oct 14;147(2):344-57. doi: 10.1016/j.cell.2011.09.029.

24.

The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma.

Huynh C, Poliseno L, Segura MF, Medicherla R, Haimovic A, Menendez S, Shang S, Pavlick A, Shao Y, Darvishian F, Boylan JF, Osman I, Hernando E.

PLoS One. 2011;6(9):e25264. doi: 10.1371/journal.pone.0025264. Epub 2011 Sep 29. Erratum in: PLoS One. 2011;6(11). doi:10.1371/annotation/a89c089f-ae9d-4453-a314-37efd5efb126.

25.

Deletion of PTENP1 pseudogene in human melanoma.

Poliseno L, Haimovic A, Christos PJ, Vega Y Saenz de Miera EC, Shapiro R, Pavlick A, Berman RS, Darvishian F, Osman I.

J Invest Dermatol. 2011 Dec;131(12):2497-500. doi: 10.1038/jid.2011.232. Epub 2011 Aug 11. No abstract available.

26.

A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?

Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP.

Cell. 2011 Aug 5;146(3):353-8. doi: 10.1016/j.cell.2011.07.014. Epub 2011 Jul 28.

27.

microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C.

Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, Quaglino E, Poliseno L, Haimovic A, Osella-Abate S, De Pittà C, Pinatel E, Stadler MB, Provero P, Bernengo MG, Osman I, Taverna D.

EMBO J. 2011 May 18;30(10):1990-2007. doi: 10.1038/emboj.2011.102. Epub 2011 Apr 5.

28.

Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression.

Rose AE, Poliseno L, Wang J, Clark M, Pearlman A, Wang G, Vega Y Saenz de Miera EC, Medicherla R, Christos PJ, Shapiro R, Pavlick A, Darvishian F, Zavadil J, Polsky D, Hernando E, Ostrer H, Osman I.

Cancer Res. 2011 Apr 1;71(7):2561-71. doi: 10.1158/0008-5472.CAN-10-2958. Epub 2011 Feb 22.

29.

A coding-independent function of gene and pseudogene mRNAs regulates tumour biology.

Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP.

Nature. 2010 Jun 24;465(7301):1033-8. doi: 10.1038/nature09144.

30.

Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation.

Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, Rameh L, Loda M, Pandolfi PP.

Sci Signal. 2010 Apr 13;3(117):ra29. doi: 10.1126/scisignal.2000594. Erratum in: Sci Signal. 2010;3(123):er6.

31.

LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis.

Maeda T, Ito K, Merghoub T, Poliseno L, Hobbs RM, Wang G, Dong L, Maeda M, Dore LC, Zelent A, Luzzatto L, Teruya-Feldstein J, Weiss MJ, Pandolfi PP.

Dev Cell. 2009 Oct;17(4):527-40. doi: 10.1016/j.devcel.2009.09.005.

32.

The proto-oncogene LRF is under post-transcriptional control of MiR-20a: implications for senescence.

Poliseno L, Pitto L, Simili M, Mariani L, Riccardi L, Ciucci A, Rizzo M, Evangelista M, Mercatanti A, Pandolfi PP, Rainaldi G.

PLoS One. 2008 Jul 2;3(7):e2542. doi: 10.1371/journal.pone.0002542.

33.

miRNAs regulate miRNAs: coordinated transcriptional and post-transcriptional regulation.

Tuccoli A, Poliseno L, Rainaldi G.

Cell Cycle. 2006 Nov 1;5(21):2473-6. Epub 2006 Sep 19.

PMID:
17102639
34.

MicroRNAs modulate the angiogenic properties of HUVECs.

Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K, Mercatanti A, Hammond S, Rainaldi G.

Blood. 2006 Nov 1;108(9):3068-71. Epub 2006 Jul 18.

PMID:
16849646
35.

Resting smooth muscle cells as a model for studying vascular cell activation.

Poliseno L, Cecchettini A, Mariani L, Evangelista M, Ricci F, Giorgi F, Citti L, Rainaldi G.

Tissue Cell. 2006 Apr;38(2):111-20. Epub 2006 Feb 8.

PMID:
16466759
36.

Identification of active siRNAs against IGF-IR of porcine coronary smooth muscle cells in a heterologous cell line.

Poliseno L, Evangelista M, Ricci F, Bonotti A, Nannipieri M, Rainaldi G.

Int J Mol Med. 2005 Apr;15(4):713-8.

PMID:
15754037
37.

The energy profiling of short interfering RNAs is highly predictive of their activity.

Poliseno L, Evangelista M, Mercatanti A, Mariani L, Citti L, Rainaldi G.

Oligonucleotides. 2004;14(3):227-32.

PMID:
15625918
38.

RNA-based drugs: from RNA interference to short interfering RNAs.

Poliseno L, Mercatanti A, Citti L, Rainaldi G.

Curr Pharm Biotechnol. 2004 Aug;5(4):361-8. Review.

PMID:
15320767
39.

Bcl2-low-expressing MCF7 cells undergo necrosis rather than apoptosis upon staurosporine treatment.

Poliseno L, Bianchi L, Citti L, Liberatori S, Mariani L, Salvetti A, Evangelista M, Bini L, Pallini V, Rainaldi G.

Biochem J. 2004 May 1;379(Pt 3):823-32.

40.

Bcl2-negative MCF7 cells overexpress p53: implications for the cell cycle and sensitivity to cytotoxic drugs.

Poliseno L, Mariani L, Collecchi P, Piras A, Zaccaro L, Rainaldi G.

Cancer Chemother Pharmacol. 2002 Aug;50(2):127-30. Epub 2002 Jun 6.

PMID:
12172977
41.
42.

Efficacy of an amphipathic oligopeptide to shuttle and release a cis-acting DNA decoy into human cells.

Citti L, Rovero P, Colombo MG, Mariani L, Poliseno L, Rainaldi G.

Biotechniques. 2002 Jan;32(1):172-4, 176-7.

Supplemental Content

Loading ...
Support Center